Andrew Ambrosy to Risk Assessment
This is a "connection" page, showing publications Andrew Ambrosy has written about Risk Assessment.
Connection Strength
0.684
-
Trajectory of Congestion Metrics by Ejection Fraction in Patients With Acute Heart Failure (from the Heart Failure Network). Am J Cardiol. 2017 07 01; 120(1):98-105.
Score: 0.414
-
Hospitalization for Recently Diagnosed Versus Worsening Chronic Heart Failure: From the ASCEND-HF Trial. J Am Coll Cardiol. 2017 Jun 27; 69(25):3029-3039.
Score: 0.105
-
Effects of Liraglutide on Worsening Renal Function Among Patients With Heart Failure With Reduced Ejection Fraction: Insights From the FIGHT Trial. Circ Heart Fail. 2020 05; 13(5):e006758.
Score: 0.032
-
A Novel In-hospital Congestion Score to Risk Stratify Patients Admitted for Worsening Heart Failure (from ASCEND-HF). J Cardiovasc Transl Res. 2020 08; 13(4):540-548.
Score: 0.031
-
Statin Therapy and Risk of Incident Diabetes Mellitus in Adults With Cardiovascular Risk Factors. Am J Cardiol. 2020 02 15; 125(4):534-541.
Score: 0.031
-
Rationale and design of the comParIson Of sacubitril/valsartaN versus Enalapril on Effect on nt-pRo-bnp in patients stabilized from an acute Heart Failure episode (PIONEER-HF) trial. Am Heart J. 2018 04; 198:145-151.
Score: 0.027
-
Influence of Clinical Trial Site Enrollment on Patient Characteristics, Protocol Completion, and End Points: Insights From the ASCEND-HF Trial (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure). Circ Heart Fail. 2016 09; 9(9).
Score: 0.025
-
The disconnect between phase II and phase III trials of drugs for heart failure. Nat Rev Cardiol. 2013 Feb; 10(2):85-97.
Score: 0.019